stockrow
Monday 9 November 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
28.05
1.14
+4.24%
Follow ALMR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 25 | 74 | 114 | +195.2% | 122 | 168 | 226 | +45.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 34.23 | 56.20 | 59.32 | +22.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (47) | (29) | (54) | (38.0%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (187.18) | (39.29) | (47.62) | +147.9 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (47) | (30) | (55) | (36.7%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 2.39 | 6.43 | 1.65 | +168.9% | |||||
| Earnings | — | — | — | — | — | — | — | — | (4.47) | (2.58) | (2.75) | (42.3%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (5.25) | (4.64) | (0.88) | (11.5%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.28) | (0.47) | (0.11) | +66.1% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (5.53) | (5.11) | (0.99) | (7.6%) | ||||||
| Book value | — | — | — | — | — | — | — | — | (12.68) | (13.76) | 4.39 | +8.6% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 11 | 12 | 38 | +9.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 3.09 | 3.09 | 17.00 | 3.1 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 6.38 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 3.21 | 3.21 | 15.10 | 3.2 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (4.22) | (4.22) | (25.15) | (4.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (55) | (54) | (61) | (2.9%) | |||||
| Capex | — | — | — | — | — | — | — | — | (3) | (5) | (8) | +82.3% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (58) | (59) | (68) | +1.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 90 | 71 | 284 | (21.2%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (80) | (20) | (227) | (74.6%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (133) | (159) | 304 | +19.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (20.60) | (20.85) | (20.6) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | (38.90) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 20.40 | (64.60) | +20.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 222 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.33 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
Alamar Biosciences, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group, Inc. | $3.1B | 21.0× | 56.4× | +41.15% (above 0%: growing) | −30.99% (below 0%: shrinking) | −55.44% (below 0%: shrinking) | 58.45% | 13.86% | Compare |
| UFPT UFP Technologies, Inc. | $2.4B | 30.6× | 31.1× | +11.57% (above 0%: growing) | +25.55% (above 0%: growing) | −35.77% (below 0%: shrinking) | 29.44% | 16.01% | Compare |
| ESTA Establishment Labs Holdings Inc. | $2.0B | — (loss-making) | — (loss-making) | +33.86% (above 0%: growing) | n/m | +145.09% (above 0%: growing) | 69.05% | (3.64%) | Compare |
| ALMR Alamar Biosciences, Inc. | $2.0B | — (loss-making) | — (loss-making) | +68.46% (above 0%: growing) | n/m | +1.07% (above 0%: growing) | 61.54% | (45.13%) | |
| INSP Inspire Medical Systems, Inc. | $1.9B | 18.4× | — (loss-making) | −7.93% (below 0%: shrinking) | n/m | −33.06% (below 0%: shrinking) | 86.05% | (13.89%) | Compare |
| BFLY Butterfly Network, Inc. | $1.7B | — (loss-making) | — (loss-making) | +51.70% (above 0%: growing) | n/m | +12.61% (above 0%: growing) | 73.02% | (41.66%) | Compare |
| ENOV Enovis Corporation | $1.6B | — (loss-making) | — (loss-making) | +1.79% (above 0%: growing) | n/m | +20.30% (above 0%: growing) | 60.83% | 0.60% | Compare |
| NVCR NovoCure Limited | $1.6B | — (loss-making) | — (loss-making) | +15.67% (above 0%: growing) | n/m | +5.54% (above 0%: growing) | 76.98% | (3.19%) | Compare |
| CNMD CONMED Corporation | $1.5B | 21.3× | 13.6× | −0.70% (below 0%: shrinking) | +635.00% (above 0%: growing) | −3.65% (below 0%: shrinking) | 56.37% | 11.07% | Compare |
| Median of peers | $1.8B | 21.1× | 31.1× | +13.62% | +25.55% | +0.95% | 64.94% | (1.29%) |